Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VirbacCHIX:VIRPP 85 Days Payable is 56.70 as of Dec. 2025, which is 54% below its 10-year median of 124.23. GuruFocus rates CHIX:VIRPP with a GF Score™ of 85/100 and a GF Value™ of €354.28 (Fairly Valued). The stock has 2 warning signs investors should review. Among 928 Drug Manufacturers companies, Virbac ranks better than 67.03% on this metric.
Virbac's average Accounts Payable for the
six
months ended in Dec. 2025 was €148 Mil. Virbac's Cost of Goods Sold for the
six
months ended in Dec. 2025 was €475 Mil.
Hence, Virbac's Days Payable for the
six
months ended in Dec. 2025 was 56.70.
The historical rank and industry rank for Virbac's Days Payable or its related term are showing as below:
CHIX:VIRPp'
s Days Payable Range Over the Past 10 Years
Min: 106.29 Med: 124.23 Max: 132.14
Current: 124.12
During the past 13 years, Virbac's highest Days Payable was 132.14. The lowest was 106.29. And the median was 124.23.
CHIX:VIRPp's Days Payable is ranked better than 67.03% of 928
companies
in the Drug Manufacturers industry
Industry Median: 88.385
vs CHIX:VIRPp: 124.12
Virbac's Days Payable
increased
from Dec. 2024 (56.55) to Dec. 2025 (56.70).
It may suggest that Virbacdelayed paying its suppliers.
The historical data trend for Virbac's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:VIRPP vs LLY, JNJ, ABBV: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Virbac's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virbac Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Virbac's Days Payable distribution charts can be found below:
* The bar in red indicates where Virbac's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Virbac's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Virbac (CHIX:VIRPP) has a Days Payable of 56.70 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Virbac and its competitors. This is 54% below median its historical median of 124.23. Over the past decade, Virbac's Days Payable has ranged from 106.29 to 132.14. According to the industry distribution chart, Virbac ranks #306 out of 928 companies in the Drug Manufacturers industry, placing it in the top 33%.
Is Virbac's Days Payable too high?
Virbac's current Days Payable of 56.70 is 54% below median its 10-year median of 124.23. Over the past 10 years, this metric has ranged from a low of 106.29 to a high of 132.14. The Drug Manufacturers industry median Days Payable is 88.39. Virbac's value of 56.70 is 35.8% below this industry median. Based on the distribution chart, Virbac ranks #306 out of 928 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Virbac has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Virbac's Days Payable compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Virbac ranks #306 out of 928 companies for Days Payable. This puts Virbac in the upper half of its industry. The industry median Days Payable is 88.39. Virbac's value of 56.70 is 35.8% below this benchmark. Historically, Virbac's own Days Payable has ranged from 106.29 to 132.14 over the past decade. While the company's 10-year median is 124.23 vs. the industry median of 88.39, Virbac has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.39, based on 928 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virbac's current Days Payable of 56.70 is 35.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Virbac and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virbac's current Days Payable is 56.70, which is 54% below median its own 10-year median of 124.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virbac stock overvalued right now?
Based on GuruFocus' analysis, Virbac (CHIX:VIRPP) is currently considered Fairly Valued. The stock's GF Value™ is €354.28, compared to a current price of €336.75 — trading 4.9% below its estimated fair value. The current Days Payable is 56.70, which is 54% below median its 10-year median of 124.23 and 35.8% below the Drug Manufacturers industry median of 88.39. Virbac's overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Virbac (CHIX:VIRPP), the current Days Payable is 56.70 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virbac (CHIX:VIRPP) Overvalued in 2026?
Based on GuruFocus' analysis, Virbac stock appears to be undervalued.
The current stock price of €336.75 is trading 4.9% below its estimated GF Value™ of €354.28.
GuruFocus considers Virbac to be Fairly Valued.
Key valuation signals for CHIX:VIRPP:
Days Payable: 56.70 (54% below median its 10-year median of 124.23)
GF Value™: €354.28 vs. price of €336.75 (4.9% below fair value)
Industry Position: 35.8% below the Drug Manufacturers median (#306 of 928)
No single metric tells the full story. See the CHIX:VIRPP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
85GF Score
Get the complete analysis for CHIX:VIRPP
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:VIRPP has been successfully added to your 
